Lineage Cell Therapeutics
LCTX
116 hedge funds and large institutions have $138M invested in Lineage Cell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 12 closing their positions.
67% more capital invested
Capital invested by funds: $83M → $138M (+$55.2M)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
6.02% more ownership
Funds ownership: 43.54% → 49.56% (+6%)
1% more funds holding
Funds holding: 115 → 116 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
Top Buyers
| 1 |
BC
Broadwood Capital
New York
|
+$7.63M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.09M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.55M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.46M |
| 5 |
RA
Raffles Associates
New York
|
+$1.22M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$563K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$473K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$415K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$194K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$113K |
LCTX Hedge Fund Activity: Q1 2024 in Review
116 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2024, worth a combined $138M — up 67% from $83M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LCTX positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $7.63M. The largest seller was Morgan Stanley, cutting an estimated $563K.
- 116 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2024, up from 115 in Q4 2023.
- Funds reported $138M of Lineage Cell Therapeutics stock for Q1 2024, up 67% quarter-over-quarter.
- 15 funds opened new Lineage Cell Therapeutics positions in Q1 2024 and 12 closed out, a net change of +3 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2024 was Broadwood Capital, an estimated $7.63M added.
- The largest Lineage Cell Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $563K sold.
Based on aggregated 13F filings for Q1 2024.